Jiaxin Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/394975/publications.pdf

Version: 2024-02-01

		361413	377865
86	1,475	20	34
papers	citations	h-index	g-index
96	96	06	2403
90	90	96	2403
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Management of stage I occult uterine leiomyosarcoma: effects of morcellation, second-look surgery, and adjuvant treatments on survival. Annals of Translational Medicine, 2022, 10, 127-127.	1.7	2
2	Low-grade endometrial stromal sarcoma with intracaval or intracardiac extension: a retrospective study of eight cases. Archives of Gynecology and Obstetrics, 2022, , 1.	1.7	0
3	Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity. Frontiers in Oncology, 2022, 12, 812346.	2.8	7
4	Decidualized ovarian endometrioma mimicking malignancy in pregnancy: a case report and literature review. Journal of Ovarian Research, 2022, 15, 33.	3.0	5
5	Early stage ovarian immature teratoma, surveillance or chemotherapy after surgery? A propensity score matched analysis. Gynecologic Oncology Reports, 2022, 40, 100976.	0.6	1
6	Analysis of Outcomes and Prognostic Factors after Fertility-Sparing Surgery in Patients with Early Stage Juvenile Granulosa Cell Tumor of the Ovary: Experience from a Tertiary Center. Journal of Pediatric and Adolescent Gynecology, 2022, 35, 486-491.	0.7	5
7	Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study. Gynecologic Oncology, 2022, 165, 446-452.	1.4	6
8	Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes. Oncogene, 2022, 41, 3093-3103.	5.9	7
9	Could Adjuvant Chemotherapy Improve Prognosis for Cervical Cancer Patients with Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?. Risk Management and Healthcare Policy, 2021, Volume 14, 109-116.	2.5	1
10	Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients. OncoTargets and Therapy, 2021, Volume 14, 809-822.	2.0	8
11	Evaluation of Cervical High-Grade Squamous Intraepithelial Lesions-Correlated Markers as Triage Strategy for Colposcopy After Co-Testing. OncoTargets and Therapy, 2021, Volume 14, 2075-2084.	2.0	1
12	Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases. Archives of Gynecology and Obstetrics, 2021, 304, 1043-1053.	1.7	8
13	Oncological and Reproductive Outcomes of Cystectomy Compared with Unilateral Salpingo-Oophorectomy as Fertility-Sparing Surgery in Patients with Apparent Early Stage Pure Immature Ovarian Teratomas. Annals of Surgical Oncology, 2021, 28, 6684-6693.	1.5	1
14	Tumor Volume Predicts High-Risk Patients and Guides Initial Chemoradiotherapy for Early Cervical Cancer. Frontiers in Oncology, 2021, 11, 640846.	2.8	2
15	Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial Journal of Clinical Oncology, 2021, 39, 5534-5534.	1.6	O
16	Integrating the genomic and TCR repertoire signatures predicts prognosis in primary epithelial ovarian cancer Journal of Clinical Oncology, 2021, 39, e17547-e17547.	1.6	0
17	Analysis of the genomic landscape of yolk sac tumors reveals mechanisms of evolution and chemoresistance. Nature Communications, 2021, 12, 3579.	12.8	7
18	Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy. Frontiers in Oncology, 2021, 11, 738370.	2.8	7

#	Article	IF	CITATIONS
19	Survival Outcomes and Prognostic Predictors in Patients With Malignant Struma Ovarii. Frontiers in Medicine, 2021, 8, 774691.	2.6	5
20	Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study. European Journal of Surgical Oncology, 2020, 46, 876-882.	1.0	5
21	CYP27B1 Downregulation: A New Molecular Mechanism Regulating EZH2 in Ovarian Cancer Tumorigenicity. Frontiers in Cell and Developmental Biology, 2020, 8, 561804.	3.7	7
22	Identification of Somatic Mutations in Papanicolaou Smear DNA and Plasma Circulating Cell-Free DNA for Detection of Endometrial and Epithelial Ovarian Cancers: A Pilot Study. Frontiers in Oncology, 2020, 10, 582546.	2.8	4
23	Oncologic and Reproductive Outcomes of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: A Single Center Retrospective Study of 67 Cases. Frontiers in Oncology, 2020, 10, 647.	2.8	11
24	Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors. Oncologist, 2020, 25, e1396-e1405.	3.7	8
25	Outcomes and prognostic factors of patients with recurrent and persistent malignant ovarian germ cell tumors. Archives of Gynecology and Obstetrics, 2020, 301, 1021-1026.	1.7	3
26	<p>Importance of Standard Treatment in Prognosis of Patients with Ovarian Cancer and Associated Cerebral Infarction</p> . Clinical Interventions in Aging, 2020, Volume 15, 151-157.	2.9	3
27	Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience. Gynecologic Oncology, 2020, 157, 94-100.	1.4	16
28	Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery. International Journal of Gynecological Cancer, 2020, 30, 664-669.	2. 5	12
29	Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma. Journal of Ovarian Research, 2020, 13, 38.	3.0	11
30	Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery. Journal of Gynecologic Oncology, 2020, 31, e16.	2.2	10
31	Clinicopathological features and maternal and foetal management of pregnancy‑complicating Krukenberg tumours. Molecular and Clinical Oncology, 2020, 12, 581-587.	1.0	1
32	Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data. Scientific Reports, 2019, 9, 9924.	3.3	22
33	Low-Grade Endometrial Stromal Sarcoma and Uterine Adenosarcoma: A Comparison of Clinical Manifestations and Outcomes. Journal of Cancer, 2019, 10, 3352-3360.	2.5	14
34	Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer. Frontiers in Genetics, 2019, 10, 839.	2.3	21
35	Uterine Adenosarcoma: A Retrospective 12-Year Single-Center Study. Frontiers in Oncology, 2019, 9, 237.	2.8	13
36	The effects of hysterectomy with bilateral salpingectomy on ovarian reserve. International Journal of Gynecology and Obstetrics, 2019, 145, 233-238.	2.3	7

#	Article	IF	CITATIONS
37	Laparoscopic vs. Open Abdominal Radical Hysterectomy for Cervical Cancer: A Single-Institution, Propensity Score Matching Study in China. Frontiers in Oncology, 2019, 9, 1107.	2.8	35
38	The proteomic comparison of peripheral circulation-derived exosomes from the epithelial ovarian carcinoma (EOC) patients and non-EOC subjects. Translational Cancer Research, 2019, 8, 452-465.	1.0	7
39	Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer Journal of Clinical Oncology, 2019, 37, 5543-5543.	1.6	0
40	Piver Type II vs. Type III Hysterectomy in the Treatment of Early-Stage Cervical Cancer: Midterm Follow-up Results of a Randomized Controlled Trial. Frontiers in Oncology, 2018, 8, 568.	2.8	10
41	Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. International Journal of Oncology, 2018, 53, 2637-2646.	3.3	58
42	Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression. Oncotarget, 2018, 9, 12064-12078.	1.8	27
43	Splenectomy during cytoreductive surgery in epithelial ovarian cancer. Cancer Management and Research, 2018, Volume 10, 3473-3482.	1.9	14
44	Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors. Gynecologic Oncology, 2018, 151, 275-281.	1.4	26
45	Clinicopathological characteristics and prognosis of adult ovarian granulosa cell tumor: a single-institution experience in China. OncoTargets and Therapy, 2018, Volume 11, 1315-1322.	2.0	9
46	Prognostic factors of <scp>FIGO</scp> stage lâ€" <scp>IIA</scp> smallâ€eell neuroendocrine carcinoma of the uterine cervix. International Journal of Gynecology and Obstetrics, 2018, 142, 374-375.	2.3	4
47	Is adjuvant chemotherapy beneficial for patients with FIGO stage IC adult granulosa cell tumor of the ovary?. Journal of Ovarian Research, 2018, 11, 25.	3.0	18
48	Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing. Journal of Ovarian Research, 2018, 11, 31.	3.0	26
49	Vaginal Yolk Sac Tumors: Our Experiences and Results. International Journal of Gynecological Cancer, 2017, 27, 1489-1493.	2.5	14
50	Primary endometrioid stromal sarcomas of the ovary: a clinicopathological study of 14 cases with a review of the literature. Oncotarget, 2017, 8, 63345-63352.	1.8	15
51	Conservative management of primary vaginal endodermal sinus tumor and rhabdomyosarcoma. Oncotarget, 2017, 8, 63453-63460.	1.8	6
52	Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age. World Journal of Surgical Oncology, 2017, 15, 154.	1.9	30
53	Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Journal of Gynecologic Oncology, 2017, 28, e39.	2.2	36
54	Fertility-sparing surgery for patients with low-grade endometrial stromal sarcoma. Oncotarget, 2017, 8, 10602-10608.	1.8	22

#	Article	IF	CITATIONS
55	Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities. Oncotarget, 2017, 8, 15136-15148.	1.8	6
56	Safety and efficacy of bleomycin/pingyangmycin-containing chemotherapy regimens for malignant germ cell tumor patients in the female genital system. Oncotarget, 2017, 8, 15952-15960.	1.8	8
57	Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis. Oncotarget, 2017, 8, 41508-41517.	1.8	20
58	Metformin use and survival outcomes in endometrial cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8, 73079-73086.	1.8	12
59	Anti-Mýllerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study. Oncotarget, 2017, 8, 113920-113927.	1.8	6
60	Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. Journal of Gynecologic Oncology, 2016, 27, e40.	2.2	11
61	Tailored therapy and long-term surveillance of malignant germ cell tumors in the female genital system: 10-year experience. Journal of Gynecologic Oncology, 2016, 27, e26.	2.2	7
62	Robot-assisted surgery versus conventional laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2173-2183.	2.5	23
63	Single-Port vs Multiport Laparoscopic Hysterectomy: A Meta-Analysis of Randomized Controlled Trials. Journal of Minimally Invasive Gynecology, 2016, 23, 1049-1056.	0.6	18
64	Computerized tomography angiography in preoperative assessment of intravenous leiomyomatosis extending to inferior vena cava and heart. BMC Cancer, 2016, 16, 73.	2.6	29
65	Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells. Tumor Biology, 2016, 37, 15763-15771.	1.8	16
66	Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions. Gynecologic Oncology, 2016, 143, 526-531.	1.4	23
67	Inhibition of the long non-coding RNA MALAT1 suppresses tumorigenicity and induces apoptosis in the human ovarian cancer SKOV3 cell line. Oncology Letters, $2016, 11, 3686-3692$.	1.8	26
68	Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. Journal of Cellular and Molecular Medicine, 2016, 20, 581-593.	3.6	39
69	Characterization of exosomes derived from ovarian cancer cells and normal ovarian epithelial cells by nanoparticle tracking analysis. Tumor Biology, 2016, 37, 4213-4221.	1.8	74
70	The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study. Oncotarget, 2016, 7, 15566-15576.	1.8	21
71	Outcome of vulvar reconstruction in patients with advanced and recurrent vulvar malignancies. BMC Cancer, 2015, 15, 851.	2.6	14
72	Protective effect of gonadotropin-releasing hormone analog on the ovarian reserve in rats receiving cyclophosphamide treatment. OncoTargets and Therapy, 2015, 8, 661.	2.0	1

#	Article	IF	CITATIONS
73	Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study. BMC Cancer, 2015, 15, 270.	2.6	26
74	Characteristic and Prognostic Implication of Venous Thromboembolism in Ovarian Clear Cell Carcinoma: A 12-Year Retrospective Study. PLoS ONE, 2015, 10, e0121818.	2.5	21
75	Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients. PLoS ONE, 2015, 10, e0133498.	2.5	16
76	The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget, 2015, 6, 25520-25532.	1.8	81
77	Tumor heterogeneity has important consequences for personalized medicine in ovarian cancer. Histology and Histopathology, 2015, 30, 173-81.	0.7	8
78	Analysis of treatment modalities and prognosis on microinvasive cervical cancer: a 10-year cohort study in China. Journal of Gynecologic Oncology, 2014, 25, 293.	2.2	14
79	Neoadjuvant chemotherapy in locally advanced cervical carcinoma: which is better, intravenous or intra-arterial?. OncoTargets and Therapy, 2014, 7, 2155.	2.0	5
80	Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins. OncoTargets and Therapy, 2014, 7, 1705.	2.0	25
81	Comparative study of ovarian clearÂcell carcinoma with and without endometriosis in People's Republic of China. Fertility and Sterility, 2014, 102, 1656-1662.	1.0	42
82	Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor. Gynecologic Oncology, 2014, 134, 78-83.	1.4	21
83	Characterization and proteomic analysis of ovarian cancer-derived exosomes. Journal of Proteomics, 2013, 80, 171-182.	2.4	254
84	Detection of recurrent cervical cancer by whole-body FDG PET scans. Chinese Journal of Clinical Oncology, 2008, 5, 125-127.	0.0	1
85	Endometriosis in adolescents-analysis of 6 cases. Chinese Medical Sciences Journal, 2003, 18, 63-6.	0.4	2
86	Peripartum cardiomyopathy-report of 16 cases. Chinese Medical Sciences Journal, 2002, 17, 117-20.	0.4	1